Background: Baricitinib, an oral JAK1/JAK2 inhibitor, has shown promising results in patients with active rheumatoid arthritis (RA). We present efficacy and safety results from the phase 3 RA-BEAM study in patients with active RA and inadequate response (IR) to methotrexate (MTX). Methods: Patients with moderate to severe RA and MTX-IR were randomized 3:3:2 to placebo, baricitinib 4 mg QD or adalimumab 40 mg biweekly. All patients continued stable background MTX therapy. Non-responders were rescued at week 16. At week 24, patients receiving placebo switched to baricitinib 4 mg QD. The study compared baricitinib, placebo and adalimumab using multiple endpoints, including non-inferiority and superiority testing; the primary endpoint was baricitinib versus placebo ACR20 response at week 12. Results: Of 1305 randomized patients, 83%, 88% and 87% completed week 52 in the placebo, baricitinib and adalimumab groups, respectively; rescue rates were 27%, 9% and 15%, respectively. ACR20 response at week 12 was higher for baricitinib versus placebo (p .001; Table 1 ). At weeks 12 and 24, significant improvements were seen for baricitinib versus placebo in ACR20/50/ 70 and DAS28, CDAI and SDAI low disease activity and remission rates, many by week one. Baricitinib was superior to adalimumab in ACR20 response rates at weeks 12, 24 and 52, and in DAS28-CRP 3.2 at weeks 12 and 52. Change in mTSS at weeks 24 and 52 was significantly lower for baricitinib versus placebo (Table) . At week 24, more baricitinib patients had improved physical function and reduced fatigue and pain versus placebo and adalimumab (Table) . During weeks 0-24, more treatment-emergent AEs occurred with baricitinib and adalimumab versus placebo (71%, 67%, 60%); serious AE rates were 5%, 2% and 4%, respectively. By week 52, treatmentemergent AE rates for baricitinib versus adalimumab were 79% versus 77% and serious AE rates were 8% versus 4%; serious infection rates were similar across groups; three major cardiovascular events (2 baricitinib, 1 adalimumab), three deaths (2 baricitinib, 1 adalimumab), one tuberculosis case (adalimumab), and five malignancies (2 baricitinib, 3 placebo) were reported. Conclusion: In patients with moderate to severe RA and MTX-IR receiving background MTX, addition of baricitinib was associated with significant clinical improvements versus placebo and adalimumab, with an acceptable safety profile.
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Methods: Patients in MOBILITY were initially randomized to placebo or sarilumab 150 or 200 mg every 2 weeks (q2w) subcutaneously for up to 1 year. Early rescue with open-label sarilumab 200 mg q2w was allowed for insufficient response after week 16. After completion of MOBILITY, patients were eligible for enrollment in EXTEND, in which all patients received active treatment (sarilumab 200 mg q2w after final dose selection) þ MTX. DAS28-CRP and clinical disease activity index (CDAI) assessed clinical efficacy. Radiographs from patients at baseline and subsequent second and third years were centrally read by 2 readers independently. Linear extrapolation was applied at year 3 for patients who had data at year 2 and from an unscheduled visit between years 2 and 3 but not at year 3. Statistical analysis at year 3 was performed on the basis of patients' original randomized treatment assignment, regardless of whether they were rescued during the double-blind period (MOBILITY). Results: Of the 1197 randomized patients in MOBILITY, 901 participated in EXTEND. At year 3, after all patients had received open-label sarilumab for 2 years, percentages of patients achieving DAS28-CRP <2.6 or CDAI 2.8 were similar in patients originally treated with either dose of sarilumab or placebo, though the initial sarilumab 200 mg group exhibited the most favorable outcomes. Improvements were maintained within each group from year 2 to year 3. Three-year radiographic data were available for 755 patients; linear extrapolation was used in 29. Modified total Sharp scores at year 3 in the initial placebo and sarilumab 150 and 200 mg groups were only slightly increased since year 2. Treatment-emergent adverse events (TEAEs) occurred in 89.7% of patients over 3 years. The most common TEAEs (!10%) were neutropenia (19.4%), increased alanine aminotransferase (13.0%) and upper respiratory tract infections (12.7%). Infections were the most frequently reported serious AE (4.2/100 patient-years). Conclusion: Active treatment with sarilumab 200 mg q2w resulted in durable clinical response and stabilization of radiographic progression at 3 years irrespective of prior treatment, though the initial sarilumab 200 mg group showed the most favorable outcomes. Adverse events were consistent with the anticipated effects of IL-6 inhibition and the known safety profile of sarilumab. We hypothesized that an in vitro Treg assay could predict whether RA patients would respond to anti-TNF antibody therapy. Methods: We recruited RA patients (n ¼ 15) who were to begin adalimumab treatment. Blood samples were taken before (baseline) and 3 months after therapy. Disease activity was assessed using DAS28, CRP and ESR. Clinical response was defined as a drop in DAS28 >1.2 compared with the pre-treatment value. PBMC isolated from RA patients before adalimumab treatment were cultured for 3 day with 10mg/ml adalimumab. On day 3, flow cytomety analysed CD4 and CD8 FoxP3 expression and membrane TNF staining on CD14 þ monocytes. Treg expansion was defined as an increase of 40% compared to the unstimulated value. Results: The addition of adalimumab to PBMC from patients with active RA before adalimumab therapy resulted in a significant increase in monocyte membrane TNF expression (p ¼ 0.002) and the percentage of CD4 Treg (p ¼ 0.0049) only in patients (n ¼ 11) who subsequently responded to adalimumab therapy as assessed at 3 months post treatment. Moreover, in vitro addition of adalimumab increased the number of CD8 þ
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þ Treg in PBMC from patients taken before therapy (p ¼ 0.0049), and in the peripheral blood of responder patients analysed at 3 months post therapy. Patients whose CD4 Treg expanded over 40% have a significant improvement in their DAS28, CRP and ESR compared to pre-treatment values. The percentage of CD4 and CD8 Treg expansion by adalimumab in vitro at baseline correlated with the percentage of peripheral blood Treg in patients at 3 months post therapy (p ¼ 0.0397 and p ¼ 0.0029 respectively). Conclusion: Collectively our data not only suggest that an in vitro assay based on increasing CD4
þ Treg numbers predicts clinical response to anti-TNF therapy in RA but also implicates enhanced Treg as a mechanism of action of adalimumab. This predictive test could be of benefit not only as a potential cost saving but also prevent risks associated with exposure to anti-TNF agents in patients unlikely to respond and could represent a step forward towards personalized medicine. Disclosure statement: The authors have declared no conflicts of interest. 
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Background: Depression is common in patients with rheumatoid arthritis (RA); approximately 17% of patients experience probable depressive disorder. Poor mental health is associated with worsened long-term disease activity and physical function. RA pharmacotherapy has potential to improve mental health outcomes indirectly by improving experiences of pain, stiffness and function; and also indirectly via targeting inflammatory processes common to the aetiology of both RA and depression. The aim of this review was to quantify the impact of RA treatments on mental and physical health outcomes. Methods: A systematic search of CENTRAL, PsychINFO, Web of Science, MEDLINE, EMBASE and CINAHL was performed from inception to March 2016. Randomized trials including pharmacological treatments were eligible; generic pain relief medication or alternative and complementary therapies were excluded. The primary outcome of interest was mental health, and data on physical health outcomes were collected as secondary outcome data. Pairwise meta-analysis (PMA) created pooled effect sizes and 95%CIs for comparisons of all treatments versus comparators (active or placebo). Network metaanalysis (NMA) provided effect size estimates of biologics versus DMARDs using indirect comparisons of different treatment modalities.
Results: A total of 58 studies were included in the PMA and 48 in the NMA, representing data from 28 specific drugs and 34,087 patients (mean 77.4% female, aged 47-62 years). The SF-36 was the most common mental health outcome measurement used. The results of the overall PMA and NMA by mode of action are shown in Table 1 . Targeted RA treatment have small effects on mental health outcomes, typically half the size of effect on physical health outcomes. There were no significant differences in effectiveness between treatment modes of action, although SUCRA rankings show that biologics targeting anti-IL-6 have a 94% probability of being the top-ranked treatments for mental health outcomes and T-cell inhibitors (abatacept) have 83% probability of being the top-ranked treatment for physical health outcomes. Conclusion: Providing effective pharmacotherapy alone is insufficient to produce meaningful improvement in mental health outcomes for the majority. Integrated mental health care provided as part of routine physical health practice is essential to optimize both mental and physical healthcare outcomes.
O05 Background: Early intervention in rheumatoid arthritis (RA) is associated with improved outcomes in randomized trials. The National Institute for Health and Care Excellence emphasized this with the publication of 7 quality statements, which focus on rapid diagnosis and management of RA. Quality statement 2 (QS2) advises that people with suspected RA are assessed by a rheumatologist within 3 weeks of primary care referral. However, there are limited real world data confirming the value of early assessment. Here we test the hypothesis that rapid assessment in secondary care associates with achieving a good treatment response. Methods: An audit, designed as a prospective longitudinal observational study, commissioned by the Healthcare Quality Improvement Partnership, was conducted to assess early RA care in England and Wales. Adults with suspected inflammatory arthritis were eligible for recruitment between February 2014 and October 2015. Follow up data were captured over 3 months for subjects with a diagnosis of RA. Closest follow up to 3 months was utilized to calculate outcomes. Compliance with QS2 was the predictor variable. The primary outcome was good EULAR DAS response; the secondary outcome was meaningful improvement in RAID score. Logistic regression was used to estimate the associations between QS2 compliance and DAS28/RAID response. Confounders including age, gender, NHS trust, baseline DAS28 and RAID scores were considered. A complete case approach was used. Results: 136 of 146 eligible trusts submitted data. 11,752 subjects consented, 5,622 were ultimately diagnosed with RA. 94/5622 (1.7%) had incomplete data for QS2. DAS28 response was available for 2234/ 5622 (39.7%), RAID response for 901/5622 (16%). Table 1 shows baseline characteristics and response for subjects with complete data. Meeting QS2 associated with a significantly greater improvement in DAS28 and RAID scores, with an adjusted odds ratio for a good EULAR response 1.30 (1.06 to 1.60) and meaningful RAID reduction 1.26 (0.87 to 1.82). Conclusion: These real world data confirm rapid rheumatology assessment significantly predicts treatment response in terms of clinical disease activity and patient reported outcomes. Among those who met QS2, an additional 8% achieved a good EULAR response.
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